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Background/Aims: Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses 
of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum 
tolerated dose therapy. This study evaluated the feasibility and therapeutic efficacy of metronomic chemotherapy 
in patients with advanced hepatocellular carcinoma (HCC) with major portal vein thrombosis (PVT). Methods: Thirty 
consecutive HCC patients with major PVT with or without extrahepatic metastasis were prospectively allocated to 
metronomic chemotherapy consisting of epirubicin being infused through the correct hepatic artery at a dose of 
30 mg/body surface area (BSA) every 4 weeks, and cisplatin (15 mg/BSA) and 5-fluorouracil (50 mg/BSA) every week for 
3 weeks, with intervening 1 week breaks. The treatment response was assessed using response evaluation criteria in 
solid tumors (RECIST). Results: In total, 116 cycles of metronomic chemotherapy were administered to the 30 patients, 
with a median of 3 cycles given to individual patients (range, 1-15 cycles). Six patients (20.0%) achieved a partial 
response and six patients (20.0%) had stable disease. The median time to disease progression and overall survival were 
63 days (range, 26-631 days) and 162 days (95% confidence interval; range, 62-262 days), respectively. Overall survival 
was significantly associated with baseline alpha-fetoprotein level (P=0.001) and tumor response (P=0.005). The baseline 
alpha-fetoprotein level was significantly associated with the disease control rate (P=0.007). Adverse events were 
tolerable and managed successfully with conservative treatment. Conclusions: Metronomic chemotherapy may be a 
safe and useful palliative treatment in HCC patients with major PVT. (Korean J Hepatol 2012;18:32-40)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common 
cancer and the third leading cause of death from cancer 
worldwide.
1 Currently, surgical resection or liver transplantation 
is the curative treatment for HCC. However, only a minority 
of patients with HCC are eligible for these treatments 
because most have advanced disease at their first diagnosis 
and/or underlying cirrhosis. Chemotherapy including systemic 
chemotherapy, hepatic artery infusion chemotherapy 
(HAIC), and transcatheter arterial chemoembolization (TACE) 
was commonly used for palliative treatment for advanced Hyun Young Woo, et al. Metronomic chemotherapy in HCC patients  33
HCC.
Conventional chemotherapy is based on maximum tolerated 
dose (MTD) chemotherapy, which means use of a single 
dose or a short course of the highest dose tolerable whose 
toxicity is not life-threatening. MTD chemotherapy mainly 
targets proliferating tumor cells.
2,3 However, with repeated 
MTD chemotherapy, HCC cells can readily acquire 
resistance to the chemotherapeutic agent and undesirable 
side effects normally associated with conventional cytotoxic 
chemotherapy are often observed.  Patients with HCC tend 
to experience more severe toxicities related to chemotherapy 
compared to patients with other cancers, due to underlying 
liver cirrhosis. Therefore, systemic chemotherapy using this 
regimen has been reported to be unsuccessful in HCC.
4 As a 
result, there is growing need for new chemotherapeutic 
strategy in patients with HCC.
Metronomic chemotherapy involves the administration of 
a chemotherapeutic  drug  at  a reduced  dose  compared  
with  conventional  MTD chemotherapy,  but  at  regular and  
more frequent intervals, with no long intervening rest 
periods.
5 Recent preclinical studies in various cancer models 
have demonstrated the anti-tumor and anti-angiogenesis 
efficacy of metronomic chemotherapy.
6-8 Our previous study 
additionally showed  that  metronomic  chemotherapy scheduling  
is  at  least  as  efficient  as  MTD  therapy  in  suppressing  
the growth  of  HCC tumors,  and is less  toxic  in  a  HCC  
model  with  associated liver cirrhosis. Furthermore, an anti- 
angiogenic effect was evident and manifest as inhibition of 
tumor endothelial cells.
9 
Despite the implied potential value of metronomic 
chemotherapy, it has been scantly utilized in patients with 
HCC. In this pilot study, the feasibility and therapeutic 
efficacy of metronomic chemotherapy using conventional 
chemotherapeutic agents was evaluated in patients with 
advanced HCC with portal vein invasion. 
PATIENTS AND METHODS
Patients
Between June 2005 and June 2009, 30 patients with 
intractable and advanced HCC were recruited to this pilot 
trial of low dose metronomic chemotherapy. Intractable and 
advanced HCC was defined as HCC with portal vein 
invasion, infiltrative type and/or refractory to surgical 
resection or nonsurgical intervention (transcatheter arterial 
chemoembolization, radiofrequency ablation and percu-
taneous ethanol injection). A diagnosis of HCC was based 
on either pathologic confirmation or radiologic findings 
with an elevated level of serum alpha-fetoprotein (AFP) 
(>400 ng/mL) in the setting of liver cirrhosis. Initially, for 
inclusion into the study, patients eligible patients met the 
following criteria: >18-years-of-age, Eastern Cooperative 
Oncology Group (ECOG) performance status of 0-1, adequate 
liver function defined as Child-Pugh score of ≤7, acceptable 
blood cell counts (absolute neutrophil count of ≥1,500 
cells/mm
3, platelet count ≥60,000 cells/mm
3, white blood 
cell count ≥4,000 cells/mm
3), serum creatinine level ≤1.5 
mg/dL, and vascular accessible lesion for the implantation 
of a chemoport. However, because there was few treatment 
option for patients with advanced HCC, patient with good 
performance status and favorable liver function was enrolled 
even if they had low blood cell counts. Portal vein invasion 
was defined as having a tumor thrombus in the main trunk 
(Vp4) and the first-order branch (Vp3) of the portal vein. 
Patients were excluded if they had one or more of the 
following: evidence of hepatic decompensation including 
uncontrolled ascites, gastrointestinal bleeding or hepatic 
encephalopathy; total bilirubin level ≥3 mg/dL or prolongation 
of prothrombin time by more than 3 seconds; concurrent 
serious medical condition(s) such as underlying cardiac or 
renal diseases; or other concurrent primary malignancy. The 
trial was conducted according to the current declaration of 
Helsinki, and the protocol was approved by the institutional 
ethics committee of the Catholic University of Korea. 
Written informed consent was obtained from each patient. 
Protocol of low dose metronomic chemotherapy
Chemotherapeutic agents were delivered through a per-
cutaneous hepatic arterial catheter (chemoport) implanted at 
the time of initial hepatic arterial angiography. The catheter 
insertion and placement were performed as previously 
described.
10 The metronomic chemotherapeutic agents were 
cisplatin and 5-fluorouracil (5-FU). Cisplatin and 5-FU was 
infused weekly for 3 weeks with intervening 1 week break. 
A single dose of cisplatin and 5-FU was 15 mg/m
2 and 50 
mg/m
2, respectively. Along with the metronomic chemotherapy, 
epirubicin (30 mg/m
2) was infused monthly without use 
of lipiodol and gelfoam embolization. This protocol was 34  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 1. Baseline characteristics
Total patients (n=30)
Age (yr) 53 (27-70)
Sex (M/F) 28/2 
HBV/HCV 27/3 
Child-pugh score
  5/6/7 10/14/6 
Antiviral treatment (yes/no) 21/9 
Tumor size (cm) 12.5 (6.2-21)
Tumor stage  
  AJCC (IIIA/IV)
* 15/15 
  B C L C  ( B / C ) 1/29 
Portal vein invasion
  B r a n c h 23
  M a i n 7  
Extrahepatic metastasis (yes/no) 15/15 
Tumor type   
(multinodular/massive/infiltrative)
3/6/21 
Previous treatment (yes/no) 15/15 
  T A C E 9
  R F A 1
  Radiation therapy 1
  Hepatic arterial infusion chemotherapy 1
  TACE+RTx 1
  T A C E + R F A + R T x 1
  Resection+TACE 1
AFP (ng/mL) 381.5 (1.9-92320)
PIVKAII (mAU/mL) 577.5 (11-8990)
WBC (/μL) 5160 (2160-13470)
Platelet (×10
3/μL) 146 (36-579)
Albumin (g/dL) 3.4 (2.6-4.3)
Total bilirubin (mg/dL) 0.9 (0.5-3.0)
Alanine aminotransferase (IU/L) 38.5 (20-101)
Prothrombin time (INR) 1.2 (0.9-1.4)
Values are presented as n or median (range).
*UICC TNM Classification of Primary Liver Cancer, 7th edition
(2010).
M, male; F, female; HBV, hepatitis B virus; HCV, Hepatitis C 
virus; AJCC, American Joint Committee on Cancer; BCLC, 
Barcelona Clinic Liver Cancer; TACE, transcatheter arterial 
chemoembolization; RFA, radiofrequency ablation; RTx, radiation
therapy; AFP, α-fetoprotein; PIVKA II, protein induced by 
vitamin K absence-II; WBC, white blood cell; INR, international 
normalized ratio.
Figure 1. Metronomic chemotherapy protocol. Infusion of epirubicin
through the correct hepatic artery at a dose of 30 mg/BSA every 
4  weeks and cisplatin and 5-fluorouracil (5-FU) at doses of 
15  and 50  mg/body surface area, respectively, every week for 
3  weeks, and repeated after a 1-week break.
repeated every 4 weeks and continued until disease progression 
or unacceptable toxicity was evident, or the patient refused 
to continue (Fig. 1). In case of cisplatin infusion, intravenous 
hydration was performed to prevent nephrotoxicity and an 
appropriate anti-emetic agent was given to all patients. Dose 
adjustments were made depending on the toxicity observed 
in the preceding treatment cycle. The following cycle of 
treatment was reduced by 30% in the case of repeated 
grade 2 toxicity during the preceding cycle. Treatment was 
stopped in the case of any grade 3 or grade 4 toxicity until 
resolution. If a patient required a delay of >4 weeks for 
recovery, they were excluded from the study.
Study assessments
The primary endpoint of the current study was feasibility. 
Feasibility was assessed by the proportion of patient who 
could undergo at least two complete sessions of metronomic 
chemotherapy without adverse event. The secondary 
endpoints were an objective response rate (complete 
response plus partial response [PR]), time to disease pro-
gression and overall survival. Tumor response was evaluated 
using abdominal dynamic computed tomography after every 
two complete sessions of chemotherapy. The responses were 
evaluated using Response Evaluation Criteria In Solid 
Tumors  criteria on an intention-to-treat basis.
11 The tumor 
responses were categorized as CR, PR, stable disease (SD), 
or progressive disease (PD). On computed tomography 
scans obtained after treatment, the sums of the longest 
diameter for all target HCCs was measured. Complete 
response was defined as the disappearance of any intra-
tumoral arterial enhancement in all target lesions. PR was 
defined as at least a 30% decrease in the sum of the longest 
diameter of viable (contrast enhancement in the arterial Hyun Young Woo, et al. Metronomic chemotherapy in HCC patients  35
phase) target lesions taking as reference the baseline sum 
longest diameter. PD was defined as at least a 20% increase 
in the sum of the longest diameter of viable (enhancing) 
target lesions or the appearance of one or more new lesions. 
SD was defined as a tumor status that did not meet the above 
three response criteria. For the evaluation of endpoint, the 
best response for each patient was selected. Liver function, 
renal function, complete blood counts, serum AFP, and chest 
X-ray were also evaluated at each visit. Toxicity was scored 
using the Common Terminology Criteria for Adverse Events 
(CTCAE; version 3.0)
12 at every visit. Survival and time to 
disease progression was estimated from the date of treatment 
initiation.
Statistical analyses
Continuous data were expressed as medians and ranges, 
and categorical data as percentages. Comparison between 
groups was performed using the Chi-square and/or Fisher’s 
exact tests, and Mann-Whitney U-test, as appropriate. 
Cumulative survival and time to disease progression rates 
were calculated using the Kaplan-Meier method and the 
difference between groups were compared by the log-rank 
test. A Cox proportional-hazards model was used to reveal 
independent clinical factors or groups affecting response 
rate and overall survival. Factors less than 0.1 in univariate 
analysis was further analyzed as cofactor in multivariate 
analysis. All data was analyzed using SPSS version 14.0 
software (SPSS, Chicago, IL, USA).
RESULTS
Patient characteristics
Thirty patients were enrolled into the study between June 
2005 and June 2009. Table 1 summarizes the patient’s 
baseline characteristics. The median age was 53 years 
and 93% of the patients were male. The underlying liver 
disease was predominantly hepatitis B virus infection (90%) 
and hepatic function was mostly Child-Pugh class A (80%). 
All patients had portal vein tumor thrombosis (PVT) and 
12 (40%) patients had a liver tumor burden ≥50%. At 
enrollment, 15 patients (50%) had extrahepatic metastasis in 
the lung (n=9), lymph node (n=1), bone (n=1), abdominal 
wall (n=1), both bone and lymph node (n=2) and both bone 
and lung (n=1). Fifteen patients (50%) displayed progressive 
disease to other treatments for HCC before metronomic 
chemotherapy.
Feasibility 
One hundred sixteen cycles of metronomic chemotherapy 
with a median of three cycles (mean 3.8 cycles; range, 1-15 
cycles) for each patient was administered to the 30 patients. 
Twenty two (73%) patients received at least two complete 
sessions of metronomic chemotherapy, The remained 8 
patients received one complete session but did not complete 
two session of chemotherapy due to adverse event (neutropenia, 
n=4, GI bleeding, n=1) and aggravated liver function due to 
tumor progression (n=1) or ingestion of herb (n=2). The 
median dose of anti-cancer agents per cycle was 58 mg 
(range, 35-74 mg) for epirubicin, 75 mg (range, 45-105 mg) 
for cisplatin, and 256.95 mg (range, 150-450 mg) for 5-FU. 
The cumulative median dose for each drug during the entire 
treatment was 162.5 mg (range, 35-960 mg) for epirubicin, 
225 mg (range, 60-1215 mg) for cisplatin, and 757 mg 
(range, 225-4050 mg) for 5-FU. In 15 patients with 
extrahepatic metastasis, 11 received concurrent radiation 
therapy for the metastatic lesion, while the other four 
patients did not because metronomic chemotherapy was 
prematurely terminated due to adverse events or 
progression.
Tumor response
After start of metronomic chemotherapy, tumor response 
could be evaluated in all 30 patients at a median of 36 days 
(range, 22-121 days). Of 22 patients who received at least 
two complete sessions of metronomic chemotherapy, PR 
was achieved in 23% (5/22), SD was observed in 23% (5/22) 
and PD was noted in 54% (12/22). Of 8 patients who did not 
complete two session of chemotherapy, PR was achieved in 
12.5% (1/8), SD was observed in 12.5% (1/8) and PD was 
noted in 75% (6/8). In overall, PR was achieved in 20% 
(6/30), SD was observed in 20% (6/30) and PD was noted in 
60% (18/30). Of the 12 patients with PR or SD initially, six 
patients showed PD during metronomic chemotherapy 
at a median of 102 days (range, 72-414 days) and overall 
progression rate was 80% (24/30). Total duration of 
metronomic chemotherapy was median 78 days (range, 
27-489 days). After metronomic chemotherapy, only 6 
patients out of 24 patients with progression underwent 36  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 2. Baseline factors predictive for tumor response
Tumor response
P-value
* P-value
†
PR (%) SD (%) PD (%)
Age (≤55/>55 yr) 5/1 (83/17) 2/4 (33/67) 13/6 (72/28) 0.258
Sex (M/F) 5/1 (83/17) 6/0 (100/0) 17/1 (94/6) 1.000
Cause (HBV/HCV) 6/0 (100/0) 5/1 (83/17) 16/2 (89/11) 1.000
Child-Pugh class (A/B) 3/3 (50/50) 4/2 (67/33) 17/1 (94/6) 0.033 0.297
Tumor size (≤12/>12 cm) 5/1 (83/17) 2/4 (33/67) 7/11 (39/61) 0.184
Antiviral treatment (no/yes) 0/6 (0/100) 1/5 (17/83) 8/10 (44/56) 0.138
Previous treatment (no/yes) 6/0 (100/0) 2/4 (33/67) 7/11 (39/61) 0.037 0.129
Staging
  AJCC (IIIA/IV)
‡ 4/2 (67/33) 3/3 (50/50) 8/10 (44/56) 0.875
  BCLC stage (B/C) 0/6 (0/100) 1/5 (17/83) 0/18 (0/100) 0.400
Portal vein thrombosis (branch/both) 3/3 (50/50) 4/2 (67/33) 16/2 (89/11) 0.156
Extrahepatic metastasis (no/yes) 4/2 (67/33) 3/3 (50/50) 8/10 (44/56) 0.875
Tumor type (nodular/massive/infiltrative) 0/0/6 (0/0/100) 2/1/3 (33/17/50) 1/5/12 (6/28/66) 0.136
AFP level (≤400/>400 ng/mL) 4/2 (67/33) 6/0 (100/0) 6/12 (33/67) 0.019 0.023
*P-value by univariate analysis, 
†P-value by multivariate analysis using Child-Pugh class, Previous treatment, AFP level as cofactor, 
‡UICC TNM Classification of Primary Liver Cancer, 7th edition (2010).
PR, partial response; SD, stable disease; PD, progressive disease; M, male; F, female; HBV, hepatitis B virus; HCV, hepatitis C 
virus; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein.
further treatment and remained patient did not receive 
further treatment due to aggravated liver function or 
performance status. Meanwhile, 1 patient out of 6 patients 
with objective response received further treatment and other 
patients did not receive further treatment due to stable tumor 
status after the end of metronomic chemotherapy. In overall, 
the median time to progression was 63 days (range, 26-631 
days). After the treatment, the median AFP level changed 
from 381 (range, 1.93-92320) to 371 (range, 1.62-439980) 
ng/mL. According to the treatment response, the median 
AFP level changed from 230.44 (range, 5.39-3955) to 18.41 
(range, 6.73-2703) ng/mL in patients with PR, from 51.05 
(5.15-374) to 106.57 (4.35-658) ng/mL in SD, and from 
1455.50 (range, 1.93-92320) to 2988.00 (range, 1.62-439980) 
ng/ml in PD. Of the various baseline factors, history of 
previous treatment for HCC, baseline Child-Pugh class, and 
baseline serum AFP level were significantly associated with 
tumor response on univariate analysis. Only baseline serum 
AFP level remained significant on multivariate analysis 
(Table 2). None of the 15 patients who experienced PD after 
a previous treatment showed an objective response (four SD 
and 11 PD) while six of the 15 patients (40%) who received 
metronomic treatment as the initial HCC therapy displayed 
PR (P=0.023). Tumor response was not affected by the 
presence of extrahepatic metastasis. Five patients (33%) 
with extrahepatic metastatsis showed PR or SD. Figure 2 
depicts a sample case with extrahepatic metastasis at 
baseline, in which marked tumor shrinkage was evident on a 
follow-up computed tomography scan following three 
cycles of metronomic chemotherapy. Blood samples were 
obtained from this HCC patient with lung metastasis by 
venipuncture before each weekly chemotherapy. Solid 
phase-enzyme linked immunosorbent assay (ELISA) was 
used to determine the serum values of VEGF (R & D 
Systems, Minneapolis, MN, USA). 
Survival and prognostic factors
The total follow-up time after start of metronomic 
chemotherapy was median 151 days (mean 239 days; range, 
33-721 days) and the follow-up period after the end of 
metronomic chemotherapy was 60 days (mean 131 days; 
range, 6-605 days). At the end of follow-up, 12 of 30 (40%) 
patients were still alive. The median overall survival was 
162 days (95% confidence interval 62-262 days) and Hyun Young Woo, et al. Metronomic chemotherapy in HCC patients  37
 
 
Figure 2. (A) An example case: a 54-year-old man was diagnosed with advanced hepatocellular carcinoma (HCC) with lung metastasis 
and treated with metronomic chemotherapy; (a) and (b) are initial abdominal computed tomography scans, which showed a mass in 
the caudate lobe (a) and multiple hematogenous metastatic nodules in both lungs (b). After three cycles of metronomic chemotherapy, 
the size of the tumor (c) and pulmonary metastatic lesions (d) had decreased markedly on follow-up computed tomography. (B) Serum 
vascular endothelial growth factor (VEGF) and alpha-fetoprotein (AFP) levels before and after metronomic chemotherapy in this sample 
case. VEGF decreased rapidly even after the first chemoinfusion, while the AFP response appeared after the completion of only one 
cycle of metronomic chemotherapy. 
Figure 3. Kaplan-Meier survival curve of 30 patients treated with 
metronomic chemotherapy.
6-month and 1-year cumulative survival rates were 48.7% 
and 34.8%, respectively (Fig. 3). On univariate analysis, 
baseline serum AFP level and tumor response were 
significantly associated with survival rate (Table 3). Overall 
survival was significantly longer in patients with baseline 
AFP ≤400 ng/mL (558 days) than at >400 ng/mL (121 
days; P<0.001). However, in multivariate analysis, no factor 
was found to be significantly associated with survival 
probably due to small number of enrolled patients.
Adverse events
During treatment, 36 adverse events occurred, and dose 
reduction or treatment delay was necessary in 21 patients 
(Table 4). The causes of dose reduction or treatment delay 
were neutropenia (n=14), aminotransferase elevation (n=1), 
aggravated ECOG score (n=2), creatine elevation (n=1), 
hyperbilirubinemia (n=2) and varix bleeding (n=1). Of 
these, one patient with aggravated ECOG score and one 
patient with varix bleeding started metronomic chemotherapy 
with a reduced dose. Most cases of neutropenia were 
manageable with conservative care and granulocyte colony- 
stimulating factor injection, while four patients with 
neutropenic fever had to permanently discontinue the 
treatment due to PD (n=3) and concern with recurrent 
neutropenia (n=1), and were managed with broad spectrum 
antibiotics. Meanwhile, only one of the 30 patients 
continued the treatment at the end of follow-up. Others 
stopped the treatment permanently due to tumor progression 
(n=7), hepatic failure associated with tumor progression 
(n=11), hyperbilirubinemia (n=2), noncompliance (n=4), 
femoral catheter dysfunction (n=1), aggravated ECOG score 
(n=2), varix bleeding (n=1), and neutropenia (n=1).
DISCUSSION
In preclinical models, metronomic chemotherapy has 
A B
(a) (b)
(c) (d)
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Table 3. Predictive factors for overall survival
Number
Median survival 
time
P-value
*
Sex 0.212
Male 28 162
Female  2 -
Age  0.792
≤55 yr 20 155
>55 yr 10 334
Cause 0.377
HBV  27 222
HCV   3  93
AFP level  0.001
≤400 ng/mL 16 558
>400 ng/mL 14 121
Child-Pugh class 0.443
A 24 158
B 6 2 6 1
Antiviral treatment 0.053
No 21 126
Yes  9 261
Previous treatment 0.292
No 15  86
Yes 15 158
Staging
AJCC (IIIA/IV)
† 15/15 222/162 0.637
BCLC stage (B/C) 1/29 -/162 0.988
Maximum tumor size  0.092
≤12 cm 14 334
>12 cm 16 121
Portal vein thrombosis 0.185
Branch 23 158
Main   7 558
Extrahepatic metastasis  0.606
No 17 222
Yes 13 162
Tumor type 0.900
Nodular  3 334
Massive  6 222
Infiltrative 21 155
Treatment response 0.005
PR  6 721
SD  6 -
PD   18 152
*P-value by univariate analysis, 
†UICC TNM Classification of 
Primary Liver Cancer, 7th edition (2010).
AFP,  α-fetoprotein; AJCC, American Joint Committee on 
Cancer; BCLC, Barcelona Clinic Liver Cancer; PR, partial 
response; SD, stable disease; PD, progressive disease.
Table 4. Adverse events
Any grade Grade 3/4
Neutropenia 14 4
Hyperbilirubinemia  7 6
Hepatic decompensation
  Ascites  7 7
  Varix bleeding  2 0/1
  Hepatic encephalopathy  1 1
Aggravated ECOG  2 2
Creatine elevation   1 1
Femoral catheter obstruction  1 1
Thrombocytopenia  1 0
ECOG, Eastern Cooperative Oncology Group.
several advantages in the treatment of cancer. First, it can be 
effective in treating tumors in which the cancer cells have 
developed resistance to the chemotherapeutic agent. This is 
because its target is not the drug-resistant cancer cell 
population but the drug-sensitive tumor endothelium; 
impressive anti-angiogenic and anti-tumor effects have been 
documented.
3,5,13 Secondly, because the cumulative dose 
with metronomic therapy is significantly less than with 
MTD-based chemotherapy,
14,15 it might be less acutely 
toxic, making more prolonged treatments possible and 
lessening or even removing the need for growth factor 
support to accelerate recovery from myelosuppression. 
Several clinical trials using metronomic chemotherapy 
have been reported or are underway for various type of 
malignancies.
16,17 
In HCC, metronomic chemotherapy has rarely been tried 
because  systemic  chemotherapy  using  conventional  cytotoxic  
agents has  not  been  effective  in  HCC  therapy.
4 To our 
knowledge, this study is the first report about metronomic 
chemotherapy in patients with HCC. About feasibility with 
this treatment, about 70% of enrolled patients could undergo 
at least two complete sessions of metronomic chemotherapy 
without adverse event. However, treatment response could 
be evaluated in all patients including patients with single 
sessions of metronomic chemotherapy. For the response, the 
objective response rate and median survival duration of the 
30 patients were 20% and 162 days, respectively. Although 
there was no control group in this study, the dropout rate 
is slightly higher and the response rate and overall survival 
are slightly shorter than that of previous reports about Hyun Young Woo, et al. Metronomic chemotherapy in HCC patients  39
HAIC.
10,18,19 It is probably because this study included not 
only patients with advanced stage and resistant to other HCC 
treatments, but also some patients with poor liver function 
and low blood cell count. About 27% of the patients resistant 
to previous HCC treatments, 33.3% of patients with 
extrahepatic metastasis and 83.3% of patients with 
Child-Pugh class B at baseline showed PR or SD. 
In this study, metronomic dose scheduling using 
conventional chemotherapeutic agents was delivered to 30 
patients with advanced HCC with PVT via a hepatic artery 
infusion system. In general, the tumor cells in HCC receive 
their blood supply mainly from the hepatic artery, which 
supports the basic concept of transarterial chemotherapy. 
Using HAIC, chemotherapeutic agents can be delivered to 
the liver at a high concentration and lower toxicity.
19 Several 
HAIC treatments using different types of chemotherapeutic 
regimen and treatment schedule have been tried to treat 
HCC. The chemotherapeutic regimen used in this study was 
modified based on our previous reports about the efficacy of 
combination therapy of transcatheter arterial infusion of and 
systemic infusion of 5-FU for unresectable HCC.
20,21 In 
these studies, the efficacy of the epirubicin, cisplatin 
and 5-FU regimen was superior to that of conventional 
adriamycin treatment, although there was a lack of 
randomization. In the present study, the total dose of 
cisplatin and 5-FU was less than 75% of previous study, and 
one-third of the total dose was delivered weekly. Meanwhile, 
epirubicin infusion was performed monthly following a 
previously established protocol, in light of the absence of 
reports about frequent dosing HAIC using epirubicin. 
Therefore, the protocol in this study is mixed form of 
metronomic and conventional chemotherapy; additional 
studies are needed to find the best metronomic protocol for 
HCC.
With regard to adverse effects, most of the patients 
generally tolerated the metronomic chemotherapy well. 
Neutropenia was the most frequent side effect. Overall, 
hematologic complications occurred more frequently than 
we expected. In this study, the dose and schedule of 
epirubicin was not metronomic schedule but MTD schedule, 
different from 5-FU and cisplatin. This would be one of the 
causes of the frequent neutropenia. Meanwhile, hepatic 
complications were observed less frequently, although most 
of the patients had liver cirrhosis and portal hypertension. 
This was probably because there was no ischemic insult due 
to embolization and the total dose of chemotherapeutic 
agent was markedly reduced. In addition, the number of 
chemotherapy cycles and total duration of treatment were 
significantly longer than our previous HAIC study.
10 This 
means that metronomic chemotherapy might be tolerable in 
patients with liver cirrhosis. However, the long term 
systemic effect of each chemotherapeutic agent should not 
be overlooked and might be a cause of neutropenia. Whether 
the benefits of metronomic chemotherapy outweigh the 
adverse consequences needs to be investigated, especially 
since the present study design did not include a control arm 
such as MTD chemotherapy. 
Among the various pretreatment factors, only serum AFP 
level was significantly associated with improved patient 
survival. Moreover, patients with a serum AFP level ≤400 
ng/mL had a better tumor response than those with an AFP 
level >400 ng/mL. It is very important to know who would 
respond or not respond to a specific treatment before that 
treatment is undertaken. One study reported that patients 
with low serum AFP respond better to 5-FU.
22 However, it is 
unclear whether serum AFP level could be exploited as a 
prognostic factor for not only 5-FU containing chemotherapy 
but also all kinds of metronomic chemotherapy, regardless 
of regimen. There was no control group (i.e., maximal 
tolerated dose chemotherapy) in this study. However, all 
included patients had main or first branch portal vein 
invasion. Therefore, conventional TACE using epirubicin, 
cisplatin and 5-FU might be inappropriate in those 
patients. Instead, we tried to compare the efficacy and 
safety of metronomic chemotherapy with historical control 
using HAIC. Secondly, a previous report about 
metronomic chemotherapy documented an anti-angiogenic 
effect using VEGR-2 expression in tumor or serum VEGF, 
TSP1 and VEGFR1 levels.
9 However, because there was no 
stored serum or tissue in most of the present patients, the 
anti-angiogenic effect of metronomic chemotherapy could 
not be evaluated with those factors. Instead, VEGF data of 
one sample case was available (Fig. 2); the results suggest 
that VEGF could be a potential predictive marker for an 
anti-angiogenic effect of metronomic chemotherapy. 
In conclusion, this pilot study indicates that metronomic 
chemotherapy using hepatic arterial infusion of cisplatin and 
5-FU might be a feasible and promising treatment approach 
for patients with advanced HCC with portal vein invasion 
without other treatment options. More studies will be needed 40  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
to confirm the efficacy and safety of metronomic chemotherapy 
for patients with advanced HCC.
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